Otsuka and Lundbeck enter "historic" CNS alliance as patent expiries loom
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical and Lundbeck have entered into what they describe as an "historic" major global alliance in the CNS area worth up to $1.8 billion to the Japanese firm that will initially focus on a joint development and commercialisation programme for two Otsuka products for schizophrenia.